<DOC>
	<DOCNO>NCT02714959</DOCNO>
	<brief_summary>The purpose study determine whether low-dose IL-2 effective refractory autoimmune encephalitis .</brief_summary>
	<brief_title>IL-2 Refractory Autoimmune Encephalitis</brief_title>
	<detailed_description>Autoimmune encephalitis recently recognize etiology encephalitis mediate various autoantibody target neural cell synapsis . The response immunotherapy generally good , considerable proportion patient autoimmune encephalitis unfavorable clinical outcome . Recently , depletion regulatory T cell ( Treg cell ) report variable autoimmune diseases multiple study show low-dose interleukin-2 ( IL-2 ) specifically activate Treg cell control autoimmunity inflammation . Protocol : This study single arm open-label study assess clinical response administration low-dose IL-2 autoimmune encephalitis patient refractory first- second-line immunotherapy . Objective : To assess efficacy low-dose IL-2 autoimmune encephalitis , resistant first- second- line immunotherapy . Methods : This single arm open-label study . Each patient receive four cycle subcutaneous Proleukin ( Interleukin-2 , IL-2 ) ( Week-1 ; 1.5 million IU ( MIU ) /d Day-1 Day-5 , Week-3 , -6 , -9 ; 3MIU/d Day-1 Day-5 ) hospital . The patient follow 3 month ( Week-21 ) . Primary outcome - clinical efficacy modify Rankin Scale Secondary outcome - Immunologic follow-up Treg cell , , IL-2 therapy , quality life , cognitive function , side effect low-dose IL-2</detailed_description>
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Hashimoto Disease</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<criteria>Age &gt; 18 year Clinical diagnosis autoimmune encephalitis Positive autoantibody ( serum CSF ) : NMDAR , antileucinerich glioma inactivated1 ( LGI1 ) , contactinassociated proteinlike 2 ( CASPR2 ) , αamino3hydroxy5methyl4isoxazolepropionic acid receptor ( AMPA ) 1 , AMPA2 , GABABR , antiHu , Yo , Ri , Ma2 , CV2/collapsing response mediator protein 5 ( CRMP5 ) , amphiphysin , glutamic acid decarboxylase ( GAD ) Refractory firstline ( highdose steroid intravenous immunoglobulin ) second line ( rituximab cyclophosphamide ) immunotherapy Written inform consent form . low hemoglobin &lt; 8.0 g/dL , absolute neutrophil count &lt; 1600/mm3 , lymphocytes &lt; 600/mm3 , platelet &lt; 140,000/mm3 heart failure ( ≥ grade III NYHA ) , hepatic insufficiency ( aspartate amino transferase &gt; 200 IU/L , amino alanine transferase , &gt; 200 IU/L ) , lung failure Positive HIV serology , active hepatitis B Significant abnormality chest Xray link disease investigation Infection Other progressive neurological degenerative disease . Poor venous access allow repeat blood test pregnant lactate woman</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>